Kalaris Therapeutics, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kalaris Therapeutics announced expanded Phase 1a SAD results for TH103 in neovascular AMD (17 treatment-naive + 3 treatment-experienced patients, all completed 6-month follow-up). Key findings: mean 9.2-letter BCVA improvement at Month 1; 27–53× lower plasma Cmax than leading anti-VEGF agents; 29% of patients required no retreatment over 6 months, 41% not retreated until ≥4 months. Safety: no IOI cases at 2.5 mg with manufacturing batch #2; one transient IOI at 5 mg. Phase 1b/2 enrollment ongoing; preliminary data expected 1H 2027; cash runway extends to Q4 2027.
Why this rating
Strong early clinical efficacy and durability signals in rare orphan/specialty retinal indication; meaningful progress de-risks lead program for $12.6M-cap micro-company. However, only Phase 1a—regulatory path remains long; no Phase 3 initiation yet.
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.